Clinical study on the thrombolytic effect with different doses of urokinase in acute myocardial infarction. The Collaborative Research Group on Thrombolysis.
OBJECTIVE
To investigate the effects of different doses of intravenous domestic urokinase.


METHODS
One thousand and twenty three cases of acute myocardial infarction within 6 hours after acute onset were divided randomly into two groups with 539 cases in the low dose group (urokinase 22,000IU/kg, total dose not lower than 1.2 million) and 484 in the high dose group (30,000IU/kg, total dose not more than 2.4 million). The patency of infarct-related coronary artery was assessed by uniform clinical criteria.


RESULTS
In the low and high dose groups the patency rates were 67.3% and 67.8% respectively (P > 0.05); 4-week mortalities were 9.5% and 8.7% respectively (P > 0.05). Frequency of severe complications had no statistically significant difference between the two groups. Adverse bleeding was a little more frequent in the high than in the low dose group, and fatal cerebral hemorrhage in 2 cases occurred in the high dose group.


CONCLUSIONS
Low dose urokinase, 22,000 IU per kg body weight with a total dose not lower than 1.2 million IU, is not only equally effective as high dose but also safer.
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000008:administration & dosage*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator